Celldex Therapeutics (CLDX) is a clinical-stage biotechnology company that focuses on developing targeted therapies for rare and difficult-to-treat diseases, specializing in immuno-oncology and ...
Novartis is just months away from filing for approval of oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria – also known as chronic hives – after reporting long ...
In spite of treatment advances, chronic urticaria continues to impair patients' health-related quality of life (HRQoL) and drive up direct and indirect healthcare costs. As early as 1997 ...
Urticaria may be acute or chronic. As opposed to acute urticaria, chronic urticaria is defined by recurrent episodes occurring at least twice a week for 6 weeks (Grattan, Sabroe, & Greaves ...